Template:CCI Guideline Vasoactive Drugs TISS: Difference between revisions
Jump to navigation
Jump to search
Ttenbergen (talk | contribs) mNo edit summary |
No edit summary |
||
| Line 14: | Line 14: | ||
**Positive inotropes: dobututamine, milrinone, amrinone | **Positive inotropes: dobututamine, milrinone, amrinone | ||
**Negative inotropes: labetolol, esmolol | **Negative inotropes: labetolol, esmolol | ||
{{DiscussTask| Can you please clarify if we are to include labetalol, as the above instruction would have us exclude it? [[User:Lkaita|Lisa Kaita]] 09:26, 2024 May 9 (CDT) }} | |||
Revision as of 08:26, 9 May 2024
Template to list vasoactive drugs to ensure consistent use in T14 - Vasoactive drug IV continuous-multiple simultaneous (TISS Item) and T14 - Vasoactive drug IV continuous-multiple simultaneous (TISS Item).
Both T14 - Vasoactive drug IV continuous-multiple simultaneous (TISS Item) and T14 - Vasoactive drug IV continuous-multiple simultaneous (TISS Item):
- do not include pure antiarrhythmics -- by which we mean agents that might not ALSO be used for cardiotonic effects (such as iv beta blockers)
- include all vasoactive and cardio-active agents, including:
- Catecholamines: norepinephrine, epinephrine, phenylephrine, dopamine
- Other vasoconstrictors: vasopressin
- Vasodilators: nitroprusside, nitroglycerine
- Positive inotropes: dobututamine, milrinone, amrinone
- Negative inotropes: labetolol, esmolol
|
Can you please clarify if we are to include labetalol, as the above instruction would have us exclude it? Lisa Kaita 09:26, 2024 May 9 (CDT) |